Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/1/2024 | $13.00 | Outperform | Raymond James |
| 11/11/2022 | $15.00 | Buy | Jefferies |
| 5/9/2022 | $10.00 → $15.00 | Hold → Buy | Canaccord Genuity |
| 3/11/2022 | $21.00 | Overweight | Cantor Fitzgerald |
| 11/4/2021 | $25.00 → $20.00 | Market Outperform | JMP Securities |
SC 13G/A - Axogen, Inc. (0000805928) (Subject)
SC 13G - Axogen, Inc. (0000805928) (Subject)
SC 13G/A - Axogen, Inc. (0000805928) (Subject)
Raymond James analyst Jayson Bedford initiates coverage on Axogen (NASDAQ:AXGN) with a Outperform rating and announces Price Target of $13.
Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announces the launch of its newest product, Avive+ Soft Tissue Matrix™. Avive+™ is intended for use as a soft tissue barrier and is a resorbable, multi-layer amniotic membrane allograft that provides temporary protection and tissue separation during the critical phase of peripheral nerve healing. Avive+ is processed and distributed in accordance with U.S. Food and Drug Administration (FDA) requirements for Human Cellular and Tissue-based Products (HCT/P) under 21 CFR Part 1271 regulations, U.S. State regulations as a 361 human tissue product. "Product innova
Canaccord Genuity analyst Caitlin Cronin reiterates Axogen (NASDAQ:AXGN) with a Buy and maintains $15 price target.
4 - Axogen, Inc. (0000805928) (Issuer)
4 - Axogen, Inc. (0000805928) (Issuer)
4 - Axogen, Inc. (0000805928) (Issuer)
ALACHUA, Fla. and TAMPA, Fla., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the third quarter ended September 30, 2024. Third Quarter Financial Results Third quarter revenue was $48.6 million, a 17.9% increase compared to the third quarter of 2023.In the third quarter of 2024, gross margin decreased to 74.9%, down from 76.8% in the third quarter of 2023.Net loss for the quarter was $1.9 million, or $0.04 per share, compared to net loss of $4.1 million, or $0.10 per share in the third quarter of 2023.Adjusted
ALACHUA, Fla. and TAMPA, Fla., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report third quarter 2024 financial results on Thursday, November 7, 2024, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the Internet may do s
ALACHUA, Fla. and TAMPA, Fla., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced that it has completed the rolling submission process for its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®. "I am proud of the significant progress our team has made towards the regulatory transition of Avance from a tissue to a biologic," said Michael Dale, CEO and Director of Axogen, Inc. "We will continue to collaborate closely with the FDA as they review our application." The Company anticipates the FDA will notify the
10-Q - Axogen, Inc. (0000805928) (Filer)
8-K - Axogen, Inc. (0000805928) (Filer)
8-K - Axogen, Inc. (0000805928) (Filer)
PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the appointment of Peter J. Mariani as Chief Financial Officer (CFO), effective August 14, 2024. Mr. Mariani will report to Dr. Phillip Chan, Chief Executive Officer of CytoSorbents. Concurrently, Kathleen P. Bloch, CytoSorbents' current CFO, announced her retirement from the Company effective as of the close of business today, and will continue to serve in an advisory role as a consultant to enable an effective t
The Board of Directors appoints Michael Dale as new CEO and Director, effective August 9, 2024Dale replaces Karen Zaderej, who will remain in an advisory role for nine monthsCurrent Member of the Board, Paul Thomas, will be the new Chairman of the Board, effective August 9, 2024 ALACHUA, Fla. and TAMPA, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Michael Dale is appointed as chief executive officer and as a member of the Axogen Board of Directors effective August 9, 2024. He succeeds Karen Zaderej, who will remain in an advisory role for n
ALACHUA, Fla. and TAMPA, Fla., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced making Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) in connection with the employment and appointment of John Manning to the position of Area Vice President of Sales. Mr. Manning will report to Doris Quackenbush, Vice President of Sales. In connection with the commencement of his employment on January 22, 2024, and as a material inducement of employment, Mr. Manning was awarded an equity grant on February 1, 2024, consisting of (i) non-qualified stock options to purc
Raymond James initiated coverage of AxoGen with a rating of Outperform and set a new price target of $13.00
Jefferies resumed coverage of AxoGen with a rating of Buy and set a new price target of $15.00
Canaccord Genuity upgraded AxoGen from Hold to Buy and set a new price target of $15.00 from $10.00 previously
ALACHUA, Fla. and TAMPA, Fla., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the third quarter ended September 30, 2024. Third Quarter Financial Results Third quarter revenue was $48.6 million, a 17.9% increase compared to the third quarter of 2023.In the third quarter of 2024, gross margin decreased to 74.9%, down from 76.8% in the third quarter of 2023.Net loss for the quarter was $1.9 million, or $0.04 per share, compared to net loss of $4.1 million, or $0.10 per share in the third quarter of 2023.Adjusted
ALACHUA, Fla. and TAMPA, Fla., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report third quarter 2024 financial results on Thursday, November 7, 2024, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the Internet may do s
ALACHUA, Fla. and TAMPA, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the second quarter ended June 30, 2024. Second Quarter Financial Results Second quarter revenue was $47.9 million, a 25.6% increase compared to the second quarter of 2023.In the second quarter of 2024, our gross margin decreased to 73.8%, down from 77.7% in the second quarter of 2023.Net loss for the quarter was $1.9 million, or $0.04 per share, compared to net loss of $6.7 million, or $0.1